Scarica l'app Stockscreener
6.85
4.60%
-0.33
Dopo l'orario di chiusura:
6.83
-0.02
-0.29%
Precedente Chiudi:
$7.18
Aprire:
$7.25
Volume 24 ore:
11,013
Relative Volume:
0.29
Capitalizzazione di mercato:
$50.16M
Reddito:
$7.00M
Utile/perdita netta:
$-70.79M
Rapporto P/E:
-0.7069
EPS:
-9.69
Flusso di cassa netto:
$-64.34M
1 W Prestazione:
-1.30%
1M Prestazione:
+8.73%
6M Prestazione:
+73.42%
1 anno Prestazione:
+17.50%
Intervallo 1D:
$6.82
$7.25
Intervallo di 1 settimana:
$6.7567
$7.25
Portata 52W:
$3.5334
$7.45
Kezar Life Sciences Inc Stock (KZR) Company Profile
Nome
Kezar Life Sciences Inc
Settore
Industria
Telefono
650-822-5600
Indirizzo
4000 SHORELINE COURT, SUITE 300, SOUTH SAN FRANCISCO, CA
Compare KZR vs VRTX, REGN, ARGX, ALNY, ONC
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
KZR
Kezar Life Sciences Inc
|
6.85 | 50.16M | 7.00M | -70.79M | -64.34M | -9.69 |
|
VRTX
Vertex Pharmaceuticals Inc
|
469.34 | 119.23B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
745.77 | 78.84B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
700.45 | 43.35B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
313.41 | 41.57B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
284.05 | 31.51B | 5.36B | 287.73M | 924.18M | 2.5229 |
Kezar Life Sciences Inc Stock (KZR) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-10-17 | Downgrade | Jefferies | Buy → Hold |
| 2025-10-17 | Downgrade | William Blair | Outperform → Mkt Perform |
| 2023-08-11 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2023-03-16 | Downgrade | William Blair | Outperform → Mkt Perform |
| 2021-12-08 | Iniziato | Wells Fargo | Overweight |
| 2018-07-16 | Iniziato | Jefferies | Buy |
| 2018-07-16 | Iniziato | Wells Fargo | Outperform |
| 2018-07-16 | Iniziato | William Blair | Outperform |
Mostra tutto
Kezar Life Sciences Inc Borsa (KZR) Ultime notizie
Deal Watch: Enodia Turns To Kezar To Advance Sec61 Programs - Citeline News & Insights
Enodia acquires Sec61 assets from Kezar Life Sciences - bioworld.com
Enodia acquires Kezar’s Sec61 program assets for $127M potential By Investing.com - Investing.com Canada
Enodia Therapeutics Strengthens Sec61 Portfolio Through Acquisition of Preclinical Assets from Kezar - pharmiweb.com
Kezar Divests Sec61 Program to Refocus on Core Pipeline - TipRanks
Enodia Therapeutics strengthens Sec61 portfolio through acquisition of preclinical assets from Kezar Life Sciences - marketscreener.com
Enodia Therapeutics Strengthens Sec61 Portfolio Through Acquisition Of Preclinical Assets From Kezar Life Sciences - TradingView
Kezar Life Sciences Sells Sec61 Program to Enodia Therapeutics for Upfront Cash, Up to $127M Milestones - TradingView
Enodia pays up to $127M to deepen protein degradation research - Stock Titan
Entry Recap: Is Kezar Life Sciences Inc a play on infrastructure spendingBear Alert & Verified Chart Pattern Signals - baoquankhu1.vn
How cyclical is Kezar Life Sciences Inc. (2KZ0) stock compared to rivalsMarket Sentiment Summary & Reliable Price Breakout Signals - Naître et grandir
Layoff Watch: Why is Kezar Life Sciences Inc stock going upTake Profit & Safe Capital Growth Tips - baoquankhu1.vn
Downgrade Watch: What are Kezar Life Sciences Incs recent SEC filings showingTrade Exit Report & Community Trade Idea Sharing - baoquankhu1.vn
KZR Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Quarterly Trades: Will CRISPR Therapeutics AG benefit from government policyJuly 2025 Technicals & Reliable Price Breakout Alerts - baoquankhu1.vn
Aug Analyst Calls: Why is Kezar Life Sciences Inc stock going upInsider Buying & Safe Capital Growth Trade Ideas - baoquankhu1.vn
Activity Recap: Is Kezar Life Sciences Inc undervalued by DCF analysisTrade Risk Summary & Low Risk Growth Stock Ideas - baoquankhu1.vn
Aug Volume: Is Kezar Life Sciences Inc undervalued by DCF analysisBull Run & Weekly Return Optimization Plans - baoquankhu1.vn
Buy Signal: Will Stratus Properties Inc benefit from current market trendsPortfolio Performance Report & High Conviction Buy Zone Alerts - baoquankhu1.vn
BML Capital Management LLC Has $2.81 Million Holdings in Kezar Life Sciences, Inc. $KZR - Defense World
Will Kezar Life Sciences Inc. stock recover faster than peersProduct Launch & Technical Confirmation Alerts - mfd.ru
Kezar Life Sciences (NASDAQ:KZR) Shares Up 0.3% – What’s Next? - Defense World
How Kezar Life Sciences Inc. stock reacts to Fed rate cuts2025 Short Interest & Daily Profit Maximizing Tips - mfd.ru
Will Kezar Life Sciences Inc. benefit from government policyJuly 2025 EndofMonth & Community Trade Idea Sharing - mfd.ru
Is Kezar Life Sciences Inc. trading at a discountTrade Exit Summary & Long Hold Capital Preservation Plans - mfd.ru
What are Kezar Life Sciences Inc.’s recent SEC filings showingJuly 2025 Fed Impact & Consistent Growth Equity Picks - mfd.ru
Is Kezar Life Sciences Inc. stock positioned for long term growthTrade Exit Summary & Entry Point Strategy Guides - mfd.ru
Published on: 2026-02-09 08:28:44 - baoquankhu1.vn
Chipmakers Recap: What is the next catalyst for Kezar Life Sciences IncJobs Report & Free Safe Capital Growth Stock Tips - baoquankhu1.vn
Kezar Life Sciences, Inc. (NASDAQ:KZR) Receives Average Rating of “Reduce” from Analysts - Defense World
Sectors Review: Will Kezar Life Sciences Inc benefit from government policy2025 Geopolitical Influence & Free Long-Term Investment Growth Plans - baoquankhu1.vn
What is the next catalyst for Kezar Life Sciences Inc.July 2025 News Drivers & Community Consensus Stock Picks - bollywoodhelpline.com
ETF Watch: Will OXLCG benefit from geopolitical trendsJuly 2025 Patterns & Low Drawdown Trading Techniques - baoquankhu1.vn
Growth Review: Should I hold or sell Kezar Life Sciences Inc now2025 Key Lessons & Intraday High Probability Alerts - baoquankhu1.vn
Layoff Tracker: SonomaBio Downsizes To Extend Runway - BioSpace
Sentiment Watch: Why Kezar Life Sciences Inc stock could rally in 2025Market Activity Summary & Free Technical Confirmation Trade Alerts - Bộ Nội Vụ
Published on: 2026-01-12 22:48:52 - ulpravda.ru
Kezar Life Sciences (KZR) to Discuss Zetomipzomib with FDA - GuruFocus
Kezar Life Sciences: FDA Division Grants Type C Meeting To Discuss Development Of Zetomipzomib - Nasdaq
Kezar Life Sciences Announces Regulatory Update on Zetomipzomib Program in Autoimmune Hepatitis - The AI Journal
Why Kezar Life Sciences Inc. stock appeals to dividend seekersMarket Movers & Stepwise Entry/Exit Trade Alerts - Улправда
Can Kezar Life Sciences Inc. stock hit record highs againTrade Performance Summary & Verified Momentum Stock Ideas - Улправда
How Kezar Life Sciences Inc. stock performs in rate cut cyclesMarket Activity Summary & Daily Chart Pattern Signal Reports - Улправда
How Kymera Therapeutics, Inc. stock performs during market volatility - ulpravda.ru
How geopolitical tensions affect Kezar Life Sciences Inc. stockBull Market Opportunities & High Yield Investment Portfolio - Улправда
Discontinued operations of Kezar Life Sciences Inc – GETTEX:2KZ0 - TradingView — Track All Markets
What drives Kezar Life Sciences Inc stock priceGap Up/Gap Down Analysis & Free High Yield Investment Strategies - Early Times
Financial Contrast: BioXcel Therapeutics (NASDAQ:BTAI) and Kezar Life Sciences (NASDAQ:KZR) - Defense World
Kezar Life Sciences (KZR) Upgraded to Buy: Here's What You Should Know - sharewise.com
Forecast Cut: Why Kezar Life Sciences Inc stock is seen as undervalued2025 Price Momentum & Daily Chart Pattern Signal Reports - Bộ Nội Vụ
Kezar Life Sciences Inc. (KZR) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Kezar Life Sciences Inc Azioni (KZR) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.48%
1.21%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):